Eukystol
Vertebral Column Disorder
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Western Michigan University School of Medicine
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Vertebral Column Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eukystol (this asset) | Western Michigan University School of Medicine | Approved | BB · 64 |
| Oxycodone | Grünenthal GmbH | P4 | BBB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Nepenthe | MedtronicNeuro | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
| Propofol | Medical College of Wisconsin | P4 | BB |
| Duloxetine | University of Pittsburgh | P4 | BB |
+31 more in the Vertebral Column Disorder cohort
Other indications for Eukystol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Psychotic Disorder | — | P4 | BBB · 76 |
| Schizoaffective Disorder | — | P4 | BBB · 72 |
| Headache Disorder | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Eukystol in Vertebral Column Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/eukystol-vertebral-column-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →